A Phase I Study of LX-039 Tablets

Clinical trial NCT04097756 · COMPLETED

Trial details

NCT number: NCT04097756
Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Breast Cancer

Start date: 2020-01-07
Primary completion: 2022-08-08
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.